Inositol

Ingredients A-Z

Overview

Inositol is a form of sugar found in our body. It is a key component in numerous cellular processes, particularly in signal transduction, lipid metabolism, and insulin signalling pathways. It exists in multiple isomeric forms, with myo-inositol and D-chiro-inositol being the most physiologically relevant. These compounds serve as secondary messengers in various hormonal signalling pathways, including insulin and gonadotropins. Inositol plays a significant role in maintaining cellular function and has gained increasing attention for its therapeutic applications in recent years. It is especially well-studied in the context of polycystic ovary syndrome (PCOS), where supplementation has been shown to improve ovulatory function, insulin sensitivity, and hormonal balance. Furthermore, inositol has shown promise in mental health management, particularly in reducing symptoms of anxiety and depression, and is being explored for its potential benefits in treating metabolic syndrome, gestational diabetes, and certain neurological conditions. Given its favourable safety profile and broad range of biological functions, inositol is emerging as a valuable supplement in both clinical and preventive health strategies¹,²,³,⁴.

Key indications

Polycystic Ovary Syndrome (PCOS)

One of the most well-established indications for inositol supplementation is in the management of polycystic ovary syndrome (PCOS). Myo-inositol and D-chiro-inositol have been shown to improve insulin sensitivity, regulate menstrual cycles, and restore ovulation in women with PCOS. These effects are largely due to their role in modulating insulin signalling and improving ovarian function. Several clinical trials and meta-analyses have confirmed the efficacy of inositol in reducing serum testosterone levels, improving oocyte quality, and increasing the likelihood of spontaneous ovulation, making it a widely recommended treatment option for PCOS¹,⁵.

Mental Health Disorders

Inositol has demonstrated therapeutic potential in mental health conditions such as depression, anxiety, and obsessive-compulsive disorder (OCD). Its mechanism of action is believed to involve the modulation of neurotransmitter systems, particularly serotonin and dopamine pathways² . Clinical studies have shown that inositol may help reduce panic attacks and improve mood in individuals with depressive and anxiety disorders, offering a safe and natural alternative or adjunct to conventional pharmacotherapy²,⁶.

Gestational Diabetes Mellitus (GDM)

Inositol supplementation, particularly myo-inositol, has been studied for its preventive effects in women at risk of gestational diabetes mellitus (GDM). It is thought to improve insulin sensitivity and glucose metabolism during pregnancy, thereby reducing the incidence of GDM⁴. Randomised controlled trials have reported that myo-inositol supplementation in early pregnancy significantly lowers the risk of developing GDM in high-risk populations, including obese women and those with a family history of diabetes⁷.

Metabolic Syndrome and Insulin Resistance

Inositol is also beneficial in the management of metabolic syndrome and insulin resistance. Through its role in intracellular signalling, especially as part of the insulin pathway, inositol helps improve glucose uptake and lipid profiles. Supplementation with myo-inositol has been associated with reductions in fasting glucose, triglycerides, and waist circumference, along with improvements in HDL cholesterol, indicating its value in metabolic health and cardiovascular risk reduction²,⁸.

Adverse effects

Inositol is generally well-tolerated, but some people may experience mild gastrointestinal disturbances such as nausea, bloating, and diarrhea, especially at higher doses⁸. Individuals with bipolar disorder should use inositol cautiously, as it may trigger manic episodes or interfere with mood-stabilising medications⁹. While inositol shows promise in pregnancy, particularly for preventing gestational diabetes⁴,⁷, it should only be used under medical supervision due to limited long-term safety data.

Dosage range

Polycystic Ovary Syndrome (PCOS):
In the management of PCOS, myo-inositol is commonly administered at a dosage of 2g twice daily (totalling 4g per day), often in combination with 200mcg of folic acid. Some protocols also include a combination of myo-inositol and D-chiro-inositol in a 40:1 ratio, reflecting the physiological plasma ratio¹,⁵,¹⁰.

Mental Health Disorders:
For mental health conditions such as depression, anxiety, and obsessive-compulsive disorder (OCD), inositol has been studied at higher doses, typically ranging from 12g to 18g per day, divided into two or three doses. These elevated dosages aim to influence serotonin and dopamine pathways in the brain. While effective in some trials, such high doses may increase the risk of gastrointestinal side effects, and thus medical supervision is recommended⁶,¹¹.

Gestational Diabetes Mellitus (GDM):
To reduce the risk of gestational diabetes in high-risk pregnant women, a common dosage is 2g of myo-inositol twice daily, initiated in the first trimester and continued throughout pregnancy. This dosing has shown efficacy in improving insulin sensitivity and lowering fasting glucose levels without reported adverse effects on mother or fetus¹².

Metabolic Syndrome and Insulin Resistance:
In patients with metabolic syndrome or insulin resistance, myo-inositol is typically used at 2g to 4g per day, either as a single dose or divided into two. Studies report improvements in blood glucose levels, lipid profiles, and other metabolic markers with this dosage, especially when combined with lifestyle interventions¹¹.

Contraindications/cautions

Inositol may have potential interactions with psychiatric and metabolic medications especially Selective Serotonin Reuptake Inhibitors (SSRIs) like Sertraline and Fluoxetine and mood stabilizers like Lithium and Valproate, necessitate medical consultation before use to avoid adverse effects or altered drug efficacy¹,⁶,⁹.

Adverse effects

Dosage range

Polycystic Ovary Syndrome (PCOS):
In the management of PCOS, myo-inositol is commonly administered at a dosage of 2g twice daily (totalling 4g per day), often in combination with 200mcg of folic acid. Some protocols also include a combination of myo-inositol and D-chiro-inositol in a 40:1 ratio, reflecting the physiological plasma ratio¹,⁵,¹⁰.

Mental Health Disorders:
For mental health conditions such as depression, anxiety, and obsessive-compulsive disorder (OCD), inositol has been studied at higher doses, typically ranging from 12g to 18g per day, divided into two or three doses. These elevated dosages aim to influence serotonin and dopamine pathways in the brain. While effective in some trials, such high doses may increase the risk of gastrointestinal side effects, and thus medical supervision is recommended⁶,¹¹.

Gestational Diabetes Mellitus (GDM):
To reduce the risk of gestational diabetes in high-risk pregnant women, a common dosage is 2g of myo-inositol twice daily, initiated in the first trimester and continued throughout pregnancy. This dosing has shown efficacy in improving insulin sensitivity and lowering fasting glucose levels without reported adverse effects on mother or fetus¹².

Metabolic Syndrome and Insulin Resistance:
In patients with metabolic syndrome or insulin resistance, myo-inositol is typically used at 2g to 4g per day, either as a single dose or divided into two. Studies report improvements in blood glucose levels, lipid profiles, and other metabolic markers with this dosage, especially when combined with lifestyle interventions¹¹.

Contraindications/cautions

References :

Santamaria, A., Di Benedetto, A., & Benvenga, S. (2023). Inositols in the treatment of polycystic ovary syndrome: Recent updates. Journal of Clinical Medicine, 12(3), 789. https://doi.org/10.3390/jcm12030789
Salehi, B., Ata, A., Kumar, N. V. A., et al. (2022). The therapeutic potential of inositol and its derivatives in metabolic and endocrine disorders. Pharmaceuticals, 15(6), 736. https://doi.org/10.3390/ph15060736
Croze, M. L., & Soulage, C. O. (2020). Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie, 180, 121–130. https://doi.org/10.1016/j.biochi.2020.01.004
D’Anna, R., Di Benedetto, A., & Facchinetti, F. (2019). Myo-inositol supplementation and gestational diabetes: A review of randomized controlled trials. Nutrients, 11(5), 998. https://doi.org/10.3390/nu11050998
Facchinetti, F., Di Francesco, S., & Matteo, M. (2020). The effectiveness of inositols in treating symptoms of polycystic ovary syndrome: A meta-analysis. Gynecological Endocrinology, 36(6), 488–493. https://doi.org/10.1080/09513590.2020.1733810
Moustafa, A. A., & Abdelkareem, S. S. (2021). Inositol and its potential role in treating mental health disorders: A review. Neuroscience Letters, 759, 136003. https://doi.org/10.1016/j.neulet.2021.136003

References :

Santamaria, A., Di Benedetto, A., & Benvenga, S. (2023). Inositols in the treatment of polycystic ovary syndrome: Recent updates. Journal of Clinical Medicine, 12(3), 789. https://doi.org/10.3390/jcm12030789
Salehi, B., Ata, A., Kumar, N. V. A., et al. (2022). The therapeutic potential of inositol and its derivatives in metabolic and endocrine disorders. Pharmaceuticals, 15(6), 736. https://doi.org/10.3390/ph15060736
Croze, M. L., & Soulage, C. O. (2020). Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie, 180, 121–130. https://doi.org/10.1016/j.biochi.2020.01.004
D’Anna, R., Di Benedetto, A., & Facchinetti, F. (2019). Myo-inositol supplementation and gestational diabetes: A review of randomized controlled trials. Nutrients, 11(5), 998. https://doi.org/10.3390/nu11050998
Facchinetti, F., Di Francesco, S., & Matteo, M. (2020). The effectiveness of inositols in treating symptoms of polycystic ovary syndrome: A meta-analysis. Gynecological Endocrinology, 36(6), 488–493. https://doi.org/10.1080/09513590.2020.1733810
Moustafa, A. A., & Abdelkareem, S. S. (2021). Inositol and its potential role in treating mental health disorders: A review. Neuroscience Letters, 759, 136003. https://doi.org/10.1016/j.neulet.2021.136003

The material is prepared for informational purposes only and should not be construed as a piece of personal medical advice. Owing to each person’s varying health needs, a physician should be consulted before acting on any information provided in this material. Although every effort is made to ensure that this material is accurate, it is compiled for internal use only and should not be considered definitive. Neither VitaHealth nor its employees, or information providers shall be responsible or liable for any errors, inaccuracies, or other defects in the information contained in this publication.